Epidermal growth factor receptor (EGFR) and HER2 are cell surface receptor tyrosine kinases (TKs) that transduce growth signals through dimerization with HER family receptors. The heterodimerization of EGFR with HER2 induces a more potent activation of EGFR TK than does EGFR homodimerization. When tumor cells overexpress both EGFR and HER2, they exhibit aggressive tumor cell growth, owing to the increased potential for EGFR/HER2 heterodimerization and signaling. Gefitinib and erlotinib are EGFR TK inhibitors (EGFR TKIs) and have antitumor activity in 8-18% of patients with advanced non-small-cell lung cancer (NSCLC). Certain patient subsets are particularly responsive to EGFR TKIs. Analyses of biomarkers from patients in clinical studies of EGFR TKIs show correlations between objective tumor response and EGFR overexpression, as detected by immunohistochemistry and increased gene copy number measured by fluorescence in situ hybridization analysis. Furthermore, NSCLC tumors that overexpress both EGFR and HER2 are more sensitive to EGFR TKIs than are tumors that overexpress EGFR but are HER2 negative. Therefore, the measurement of EGFR and HER2 protein expression and the gene copy number in NSCLC tumors may have a prognostic value in NSCLC and a predictive value for identifying patients likely to benefit from an EGFR TKI. These considerations suggest that the simultaneous inhibition of EGFR and HER2 may warrant further study in patients with NSCLC.
Introduction
Agents that target the epidermal growth factor receptor (EGFR) have proven to be effective in the treatment of patients with advanced non-small-cell lung cancer (NSCLC); however, only a small subset of patients respond. Various clinical and molecular markers have been suggested to function as predictors of response to the reversible EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib. Molecular markers associated with clinical response to EGFR TKIs include EGFR protein overexpression measured by immunohistochemistry (IHC), gene copy number measured by fluorescent in situ hybridization (FISH) and the presence of specific mutations within the TK domain of the EGFR identified by mutational analysis (Lynch et al., 2004; Paez et al., 2004; Pao et al., 2004; Tokumo et al., 2005; Cappuzzo et al., 2005a) . However, the ability of these markers to consistently predict clinical response is controversial (Zhu et al., 2008) . Although some clinical trials have failed to find an association between response to gefitinib and expression of EGFR, several studies have shown that increased EGFR gene copy number, as determined by FISH, and EGFR protein overexpression correlated with improved response and overall survival (OS) (Hirsch et al., 2005; Cappuzzo et al., 2005a Cappuzzo et al., , 2007 Sequist et al., 2007) . Furthermore, increased HER2 gene copy number was also found to predict response to EGFR TKIs in EGFR-positive patients with NSCLC (Cappuzzo et al., 2005a; Soh et al., 2007) . In this review, we focus on data supporting the value of EGFR and HER2 overexpression for the prediction of response to EGFR TKIs.
EGFR and HER2 overexpression
EGFR is highly expressed in a variety of human tumors, including NSCLC, and is implicated in tumor development (Grandis and Sok, 2004; Merrick et al., 2006) . The overexpression of EGFR has been observed in both premalignant lesions and malignant tumors of the lung, and occurs in 40-80% of patients with NSCLC (Salomon et al., 1995; Grandis and Sok, 2004; Merrick et al., 2006) . EGFR overexpression was suggested to result primarily from epigenetic causes, including transcriptional activation; however, gene amplification and oncogenic viruses can also have an important function (Wong et al., 1992; Rubin Grandis et al., 1996a, b; Grandis and Sok, 2004) . In tumors, the EGFR signaling network can result in the activation of MAPK, PLCg, PI3K/AKT, the STAT transcription factors, proto-oncogene transcription factors, such as fos, jun and myc, and zinc-finger-containing transcription factors, such as Sp1 and Egr1 (Grandis and Sok, 2004) . Activation of the EGFR signaling network results in tumor growth, inhibition of apoptosis, cell migration and invasion, cellular differentiation, and transformation (Grandis and Sok, 2004) .
The overexpression of HER2 is found in patients with NSCLC and other tumors, such as prostate, brain and breast tumors but, overall, is less common than EGFR overexpression (Hirsch et al., 2002) . In patients with breast cancer, HER2 is a significant predictor of decreased OS, and the HER2-targeted monoclonal antibody, trastuzumab, is now used for the treatment of patients with HER2-overexpressing metastatic breast cancer. Some studies have shown a similar link between HER2 expression and poor prognosis in patients with NSCLC (Hirsch et al., 2002) . Approximately 18-33% of NSCLC tumors have a positive result (2 þ /3 þ ) with the HercepTest (Dako North America, Carpinteria, CA, USA) (Hirsch et al., 2002) . Positivity for HER2 varies on the basis of histology, with the highest frequency in adenocarcinomas (17-42%), followed by large-cell carcinomas (2-40%), and a low frequency in squamous carcinomas (0-5%) (Hirsch et al., 2002) . HER2 overexpression may also be linked to a chemoresistant phenotype in human NSCLC (Tsai et al., 1996) .
Predictive value of EGFR amplification and overexpression
A high EGFR gene copy number (gene amplification or high polysomy) can be detected by FISH, and several studies have shown their value for predicting response to EGFR TKIs.
In a study of 102 patients with NSCLC receiving gefitinib 250 mg/day, EGFR amplification or high polysomy correlated with response rate (RR), disease control rate (DCR), time to progression (TTP) and OS (Cappuzzo et al., 2005a) . Patients with high polysomy (X4 copies in X40% of cells) or gene amplification (ratio of the EGFR gene to chromosome X2, or EGFR gene clusters or X15 copies of EGFR per cell in X10% of cells) were classified as EGFR FISH positive. FISHpositive patients had a higher objective RR than did FISH-negative patients (36 vs 3%, respectively; Po0.001). Furthermore, median TTP was 9 months in EGFR FISH-positive patients but only 2.5 months in FISH-negative patients. Likewise, median OS was almost 19 months in patients who were FISH positive compared with 7 months in patients who were FISH negative. In this study, multivariate analysis showed the significance of a high gene copy number as a predictor of survival, with a hazard ratio (HR) of 0.44 (95% confidence interval (CI), 0.23-0.82; Po0.01). A similar study in a subset of 81 patients with NSCLC and advanced bronchoalveolar carcinoma receiving gefitinib 500 mg/day showed concordant results with a correlation between increased EGFR gene copy number detected by FISH and improved OS, which persisted on multivariate analysis (P ¼ 0.03) (Hirsch et al., 2005) .
In a subset analysis of patients enrolled in the BR.21 trial, 56 of 125 tumors assessable by FISH showed high polysomy or gene amplification (Tsao et al., 2005) . The ratio of RR to erlotinib was found to be higher among patients with a high EGFR gene copy number than in patients with a low gene copy number (20 vs 2%, respectively; P ¼ 0.03). Among patients with a high EGFR gene copy number, OS was significantly longer with erlotinib (HR, 0.44 (95% CI, 0.23-0.82); P ¼ 0.008), whereas there was no OS benefit in patients with a low gene copy number (HR, 0.85 (95% CI, 0.48-1.51); P ¼ 0.59). However, in multivariate analysis, OS was not found to be significantly influenced by the EGFR FISH status. In a recent update from that study, 34 additional samples were available for EGFR FISH analysis (n ¼ 159) (Zhu et al., 2008) . Again, there was a significant difference in RR between patients with a high and low EGFR copy number (21 vs 5%, respectively; P ¼ 0.02). Erlotinib provided a significant OS benefit to patients with a high copy number (HR, 0.43 (95% CI, 0.23-0.78); P ¼ 0.004) but not to patients with a low EGFR copy number (HR, 0.80 (95% CI, 0.49-1.29); P ¼ 0.35). However, in this updated report, the multivariate analysis showed that EGFR FISH positivity was indeed predictive of a greater OS benefit with erlotinib (P ¼ 0.005). In addition, it was found that EGFR FISH positivity was also prognostic for a poorer OS in untreated patients (P ¼ 0.025).
The ISEL trial was a double-blind, randomized, placebo-controlled, multicenter phase III study evaluating the efficacy of gefitinib in 1692 patients with refractory, locally advanced or metastatic NSCLC (Hirsch et al., 2006 ). An analysis of biomarkers and clinical response in this trial identified high EGFR gene copy number as a predictor of clinical benefit with gefitinib (Hirsch et al., 2006) . High EGFR gene copy numbers were detected in 31% of 370 patients with tissue samples available for FISH analysis, and a high EGFR protein expression was found in 70% of 379 evaluable patients. Patients with a high EGFR gene copy number who were treated with gefitinib showed a significantly longer OS than did patients with a low copy number (P ¼ 0.045). Furthermore, a high EGFR gene copy number was associated with a 39% lower risk of death in patients receiving gefitinib than in patients receiving placebo (HR, 0.61 (95% CI, 0.36-1.04); P ¼ 0.07), with a median OS of 8.3 vs 4.5 months, respectively (Figure 1) (Hirsch et al., 2006) . In contrast, there were no differences in OS in patients receiving gefitinib or placebo who had a low EGFR gene copy number. The survival benefit associated with gefitinib in patients with a high EGFR gene copy number was observed even in those with poor prognostic factors, such as smokers and patients with non-adenocarcinoma subtype tumors. In addition, this improvement in OS corresponded to a higher objective RR and time to treatment failure.
EGFR protein expression by IHC has also been shown to be positively associated with a better prognosis with EGFR TKIs, although not as strongly as high EGFR gene copy number. In patients enrolled in the BR.21 trial, a high EGFR protein expression or IHC positivity was associated with response to erlotinib (P ¼ 0.03). A univariate analysis showed that erlotinib provided a significant OS advantage compared with placebo in patients who were IHC positive (HR, 0.68 (95% CI, 0.49-0.95); P ¼ 0.02) but not in patients who were IHC negative (HR, 0.93 (95% CI, 0.63-1.36); P ¼ 0.70). However, EGFR protein expression was not found to be associated with survival in a multivariate analysis (Tsao et al., 2005) . Conversely, in the ISEL study, IHC-positive patients had significantly longer OS times with gefitinib than did IHC-negative patients (HR, 0.77 (95% CI, 0.56-1.08) vs 1.57 (95% CI, 0.86-2.87); P ¼ 0.05) (Hirsch et al., 2006) . Interestingly, although there was no difference in OS between erlotinib-and placebo-treated IHC-negative patients in the BR.21 study, IHC-negative patients in the ISEL study showed a tendency toward a shorter OS with gefitinib (HR, 1.57 (95% CI, 0.86-2.87)) (Tsao et al., 2005; Hirsch et al., 2006) . Many studies have also shown that EGFR protein expression is associated with poor prognosis (Meert et al., 2002) .
The combination of EGFR gene copy number using FISH and protein overexpression measured by IHC may be an effective predictor of benefit from gefitinib. In a study evaluating pooled data from patients enrolled in two clinical trials of gefitinib, patients with either EGFR FISH positivity or IHC positivity had improved RR, DCR and OS compared with FISH-or IHC-negative patients (Hirsch et al., 2007) . In addition, a multivariate analysis showed that both increased EGFR gene copy number and high EGFR protein expression were independent predictive variables. Patients who tested positive on both FISH and IHC analyses (42 of 179 assessable patients) had significantly better RR, DCR, progression-free survival (PFS) and OS than did patients who tested negative on both analyses (54 of 179 assessable patients): RR, 41 vs 2% (Po0.001); DCR, 76 vs 17% (Po0.001); PFS, 9 vs 2 months (Po0.001); OS, 21 vs 6 months (Po0.001). The efficacy results of patients who were either FISH negative and IHC positive or FISH positive and IHC negative (83 of 179 assessable patients) fell between those of doublepositive and double-negative patients, but were significantly better than those reported in double-negative patients. The updated results from the BR.21 study also showed a significant association between FISH/IHC positivity and an increased response to erlotinib compared with patients who were FISH/IHC negative (23 vs 3%; P ¼ 0.03) (Zhu et al., 2008) . The OS benefit provided by erlotinib was significant for patients who were FISH/IHC positive (HR, 0.37 (95% CI, 0.18-0.79); P ¼ 0.008) but not for double-negative patients (HR, 0.62 (95% CI, 0.31-1.24); P ¼ 0.17); however, the OS advantage provided by erlotinib did not differ significantly between the two groups (P ¼ 0.33).
The use of monoclonal antibodies targeted against EGFR, mainly cetuximab, has been more recently evaluated in patients with NSCLC. Results from the FLEX study, a large, randomized trial comparing cisplatin plus vinorelbine with and without cetuximab in EGFR IHC-positive patients, showed a survival benefit among patients who received cetuximab (Pirker et al., 2008) . However, although OS improvement was statistically significant (median, 11.3 vs 10.1 months, respectively; HR, 0.87 (95% CI, 0.762-0.996); P ¼ 0.044), efficacy was not improved dramatically. As with EGFR TKIs, the identification of predictive biomarkers may allow for the selection of patients for cetuximab treatment. A phase II study by the Southwest Oncology Group (SWOG 0342) evaluated concurrent chemotherapy plus cetuximab or chemotherapy, followed by cetuximab in patients with untreated advanced NSCLC. In this study, no difference in OS was observed in patients receiving paclitaxel and carboplatin concurrently with cetuximab compared with patients receiving sequential treatment (Herbst et al., 2007) . However, OS, DCR and PFS were superior in the EGFR FISHpositive population (Hirsch et al., 2008) . PFS was 6 months in FISH-positive patients compared with 3 months in FISH-negative patients, and the median OS times were 15 and 7 months, respectively, in these two groups (Hirsch et al., 2008) . These results, along with those from ISEL and BR.21, further show the predictive value of EGFR copy number for PFS and OS in patients with NSCLC treated with EGFR inhibitors.
Prognostic and predictive value of EGFR and HER2 coexpression
The synchronous expression of both EGFR and HER2 is prognostic for an increased recurrence risk and, possibly, for a lower OS in patients with NSCLC. In a clinical trial of 83 patients with NSCLC, the coexpression of EGFR and HER2 was associated with a significantly shortened OS (P ¼ 0.003) compared with that in patients whose tumors expressed high levels of EGFR or HER2 (Brabender et al., 2001) .The coexpression of EGFR and HER2 was determined to be a significant independent adverse prognostic factor on the basis of multivariate analyses. In another study of 111 patients with stage I NSCLC, those who coexpressed EGFR and HER2 showed a trend toward a shorter OS (44 vs 84 months in other patients; P ¼ 0.093) (Onn et al., 2004) . Multivariate analysis showed that, in a subset of patients with adenocarcinoma or squamouscell carcinoma, the coexpression of EGFR and HER2 was significantly correlated with a shortened OS (P ¼ 0.027).
A role for EGFR and HER2 receptor cooperation is supported by clinical data showing that patients who have an increased HER2 gene copy number and are EGFR positive by FISH or IHC have increased sensitivity to gefitinib with improved RR, DCR, TTP and OS (Table 1) (Cappuzzo et al., 2005b; Daniele et al., 2007) . In a clinical study of 102 patients with NSCLC treated with gefitinib, patients who were positive for both EGFR and HER2, as assessed by FISH, had significantly higher objective RRs to gefitinib than did patients with EGFR-negative and/or HER2-negative tumors (54 vs 7%; Po0.001) (Cappuzzo et al., 2005b) .
Likewise, patients with a high EGFR and HER2 copy number had better DCR (77 vs 33%, respectively; P ¼ 0.002), TTP (9.8 vs 2.6 months, respectively; P ¼ 0.007) and OS (20.8 vs 8.3 months, respectively; P ¼ 0.04) than did patients with EGFR-and/or HER2-negative tumors. EGFR-positive patients who were negative for HER2 showed a trend toward poorer TTP and OS than did double-positive patients, although the difference was not significant (TTP, 9.8 vs 5.3, respectively, (P ¼ 0.20); OS, 20.8 vs 9.3 months, respectively, (P ¼ 0.13)). Patients who were EGFR negative and HER2 positive, as well as patients who were double negative, had poorer prognoses than did other patients (Table 1) .
Another study showed the effectiveness of FISH/ chromogenic in situ hybridization analysis in assessing EGFR and HER2 in histological biopsy and cytological specimens from 42 patients with NSCLC (Daniele et al., 2007) . The concurrent gene gain of both EGFR and HER2 was found to be associated with response to gefitinib. In total, 10 (76.9%) of 13 patients with a genomic gain of EGFR and 9 (69.2%) of 13 patients with a genomic gain of HER2 responded to gefitinib in contrast to only 2 (6.8%) of 29 and 3 (10.3%) of 29 patients with balanced disomic cancers. The investigators in this study also defined an optimal scoring method for FISH and chromogenic in situ hybridization to identify patients with NSCLC who are likely to benefit from the administration of EGFR TKIs. FISH/chromogenic in situ hybridization analysis was suggested as the first-line test and an alternative to mutational analysis, and showed that EGFR-and HER2-balanced genomic gain was primarily because of chromosome 7 or 17 polysomy, not because of gene amplification.
Conclusion
There is substantial evidence that EGFR and HER2 overexpression has an important function in the biology of NSCLC and may have a prognostic value for patients with metastatic NSCLC. In addition, the EGFR overexpression by IHC and the gene copy number measured by FISH may be useful for predicting the response of patients to EGFR TKIs, thereby allowing the selection of appropriate candidates for therapy. The predictive 
